WO2007110225A1 - Improved crystalline material - Google Patents
Improved crystalline material Download PDFInfo
- Publication number
- WO2007110225A1 WO2007110225A1 PCT/EP2007/002687 EP2007002687W WO2007110225A1 WO 2007110225 A1 WO2007110225 A1 WO 2007110225A1 EP 2007002687 W EP2007002687 W EP 2007002687W WO 2007110225 A1 WO2007110225 A1 WO 2007110225A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- crystalline material
- dibromo
- methylethyl
- phenoxy
- hydroxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/25—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Definitions
- This invention relates to an improved crystalline material and its use in the treatment of conditions associated with thyroid disfunction.
- WO 01/60784 relates to novel compounds which are agonists of the thyroid beta receptor.
- Example 1 describes the synthesis of 3- [ [3, 5-dibromo-4- [4-hydroxy-3- (1-methylethyl) -phenoxy] - phenyl] -amino] -3-oxopropanoic acid. This compound is hereinafter referred to as Compound I, and has the formula:
- XRD powder X-ray diffraction
- DSC differential scanning calorimetry
- novel crystalline material Form N-6 of the invention may be characterised by its Fourier Transform infra-red (FTIR) spectrum.
- FTIR Fourier Transform infra-red
- any XRD, DSC or FTIR pattern will depend upon a number of factors, for example the instrument used and the degree of purity of the material. DSCs in particular, may be instrument dependent. The numbers quoted throughout this Specification refer to the use of a TA instruments MDSC-2920 machine.
- Form N-6 is provided according to the invention at a level of purity in which at least 90%, especially at least 95%, most preferably substantially all, of the Compound I present, is Form N-6.
- Compound I can itself be synthesised as described in either WO 01/60784 or US 2003/0157671. Resulting Compound I having a different physical structure from Form N-6 may then be converted into Form N-6 by a method which comprises preparing a solution of Compound I in a suitable solvent, and seeding with crystals of either Form N-5 (see below) or Form N-6, under conditions such that Form N-6 is obtained.
- a solution of Compound I may be prepared in situ and this solution used directly to obtain crystals of From N-6. It is a characteristic of Compound I that the thermodynamic equilibrium between Forms N-5 and N-6 is finely balanced. Thus, at a temperature of less than about 50°C, crystals of either Form N-5 or Form N-6 may be used to seed a solution of Compound I to prepare crystals of N-6.
- Suitable solvents in this context include, for example, water, alcohols, for example methanol, ethanol, isopropanol or hexanol, ketones, for example acetone, DMSO, esters, for example ethyl acetate, acids, for example acetic acids, nitriles, for example acetonitrile, amides, for example DMF, nitromethane or nitroethane, or hydrocarbons, for example toluene or hexane; or mixtures thereof.
- Form N-5 may be prepared as described below.
- one preferred method of preparing further Form N-6 comprises preparing a solution of Compound I in an alcohol or alcohol mixture, for example an ethanol/isopropanol mixture; adding water; optionally filtering the resulting solution; and seeding the resulting solution with crystals of Form N-6 to produce further crystals of Form N-6.
- an alcohol or alcohol mixture for example an ethanol/isopropanol mixture
- Form N-5 is generally very stable, under certain conditions it may convert to Form N-6. Accordingly, a further method of preparing Form N-6 comprises slurrying Form N-5 in an alcohol/water mixture for a sufficient period of time to allow conversion to Form N-6. An extended period of time, typically from 6 to 10 days, is generally required.
- Form N-6 has been found to have a number of advantageous properties. In particular, it is highly stable, being heat stable up to at least 170°C, and is non-hygroscopic up to a relative humidity of 95% .
- XRD X-ray diffraction
- any XRD or DSC pattern will depend upon a number of factors, for example the instrument used and the degree of purity of the material.
- Form N-5 is provided according to the invention at a level of purity in which at least 90%, especially at least 95%, most preferably substantially all, of the Compound I present, is Form N-5.
- Compound I can itself be synthesised as described in either WO 01/60784 or US 2003/0157671. Resulting Compound I having a different physical structure from Form N-5 may then be converted into Form N-5 by a method which comprises preparing a solution of the Compound I in a suitable solvent, and recrystallising under conditions such that crystals of Form N-5 are produced. Alternatively, a solution of Compound I may be prepared in situ and this solution used directly to obtain crystals of Form N-5.
- Suitable solvents in this context include, for example, water, alcohols, for example methanol, ethanol, isopropanol or hexanol, ketones, for example acetone, DMSO, esters, for example ethyl acetate, acids, for example acetic acids, nitriles, for example acetonitrile, amides, for example DMF, nitromethane or nitroethane, or hydrocarbons, for example toluene or hexane; or mixtures thereof.
- a solution of the Compound I in an alcohol is prepared, preferably at room temperature, and recrystallisation is achieved by the addition of water.
- a solution of Compound I in nitroethane may be prepared at elevated temperature, and recrystallisation achieved by cooling.
- a slurry process may be used to prepare Form N-5.
- a solution of Compound I in a suitable solvent for example an alcohol or an alcohol mixture, may be prepared, and water may be added to produce a suspension.
- the resulting slurry may then be stirred for a period of time sufficient for Form N-5 to be produced.
- Form N-5 can convert into Form N-6, and therefore care needs to be taken to minimise this conversion when preparing Form N-5. For example, extended contact (i.e. contact over several days) with certain solvents, especially alcohol solvents, should be avoided.
- Form N-5 has been found to have a number of advantageous properties.
- it is highly stable, being heat stable up to at least 170°C, and is non-hygroscopic up to a relative humidity of 95%.
- it either does not convert to other forms, or only converts very slowly; for example, if slurried in the presence of an alcohol, it is stable for a number of days, but after very long periods of time, conversion into Form N-6 may occur.
- Form N-6 and Form N-5 Similar processes may be used to make Form N-6 and Form N-5.
- the nature of the product is determined by the precise reaction conditions, which may be readily determined by the skilled man with the aid of the Examples herein.
- Form N-I has a DSC thermogram which exhibits a single exotherm with a maximum at 116+6°C (and an extrapolated onset of 111 ⁇ 6°C) .
- the heat of fusion is about 58J/g.
- a typical DSC trace of Form N-I is shown in Figure 7.
- Form N-I is less stable than either Form N-6 or Form N-5, being heat stable only up to around 125°C, and becoming hygroscopic at a relative humidity of 50%.
- Form N-I converts into Form N-5 and/or Form N-6 (depending upon the exact conditions) on being dissolved or slurried in a number of common solvents, for example alcohols such as methanol, ethanol or isopropanol, nitromethane or nitroethane, and mixtures of alcohols, for example methanol, ethanol or isopropanol, with water.
- common solvents for example alcohols such as methanol, ethanol or isopropanol, nitromethane or nitroethane, and mixtures of alcohols, for example methanol, ethanol or isopropanol, with water.
- the invention also provides a pharmaceutical composition comprising Form N-6 and/or Form N-5 together with a pharmaceutically acceptable carrier.
- the pharmaceutical composition may be formulated for and administered to humans or other mammals by any suitable method. It is preferably formulated for oral administration in solid or liquid form, or for topical administration, for parenteral injection, or for rectal administration. Suitable forms of pharmaceutical composition, and methods of administration, include those described in WO 01/60784.
- compositions according to the invention may also contain one or more other therapeutic agents. Suitable compounds for use in combination therapy are listed in WO 01/60784.
- the crystalline materials of the invention may be used for treating or preventing a condition associated with the thyroid receptor, by agonising the effects, in particular the thyroid beta receptor.
- Such conditions include obesity, hypercholesterolemia, atherosclerosis, depression, osteoporosis, hypothyroidism or subclinical hypothyroidism, non-toxic goiter, papillary or follicular thyroid cancer, glaucoma, cardiovascular disease, congestive heart failure, and skin disorders such as psoriasis, dermal atrophy, wound healing, keloids, stria, cellulite, roughened skin, actinic skin damage, lichen planus, ichtyosis, acne, psoriasis, Dernier' s disease, eczema, atopic dermatitis, chloracne, pityriasis and skin acarring.
- the present invention also provides the crystalline materials of the invention or a pharmaceutical composition according to the invention, for use in therapy; the use of such crystalline materials or composition in the manufacture of a medicament for the treatment of a condition associated with thyroid disorders; and a method of selectively agonizing the effects of the thyroid beta receptor in a mammal which comprises administering a therapeutically effective amount of a crystalline material or a pharmaceutical composition according to the invention, to the mammal.
- the dosage level required in any individual case will depend upon various factors including the route of administration and the severity of the condition being treated. Very generally, dosage levels of about 0.001 to 500, more preferably of about 0.01 to about 100, most preferably of about 0.01 to 25mg, such as 0.01 to 1 mg, of Compound I per person per day, are administered. If desired, the effective daily dose may be divided into multiple doses for purposes of administration, e.g. two to four separate doses per day.
- Figure 1 is an XRD of Form N-6.
- Figure 2 is a differential scanning calorimetry trace of
- Figure 3 is an FTIR of Form N-6.
- Figure 4 is an XRD of Form N-5
- Figure 5 is a differential scanning calorimetry trace of Form N-5.
- Figure 6 is an XRD of Form N-I, together with XRDs of Form N- 5 and Form N-6.
- Figure 7 is a differential scanning calorimetry trace of Form N-I.
- DSC traces were obtained using a 2920 MDSC V2.5F machine, by testing about 5-10mg of sample in an aluminium DSC crucible, with a temperature gradient of 10°C/min.
- Seeds (confirmed to be pure N-5 by DSC, IR and XRD) were added in this experiment as a slurry (O.lg slurried in 20ml water) , very slowly at 200 ⁇ l/min, during which the solution temperature was kept constant. After 1 hour the solution became cloudy. Additional water (about 30ml) was added at the same rate. Addition of water was then stopped since the solution became opaque and viscous. After 17 hours at 25°C, the solution was cooled down to 8 0 C by 0.33°C/min and filtered. Form N-6, whose identity was confirmed by XRD, was obtained.
- Solid Compound I consisting mostly of Form N-5 prepared as in Example 2 below, was slurried in an ethanol : water mixture (1:5 vol) at 20°C for 8 days. Form N-6 was produced.
- Example 2C Method C A solution of Compound I corresponding to the saturation concentration at 7O 0 C was prepared by dissolving Form N-I in 20ml of nitroethane and heating the solution to 78°C. The solution was then cooled to 65°C. When the crystallizer temperature reached the desired temperature, the temperature was kept constant 24 hours. Nucleation was not observed. Temperature was then decreased to 64 °C and after 24 hours to 63 0 C. Nucleation started after 4 days. This experiment was repeated three times and in all cases Form N-5 was formed.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Biomedical Technology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Organic Insulating Materials (AREA)
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2007229718A AU2007229718A1 (en) | 2006-03-28 | 2007-03-27 | Improved crystalline material |
US12/225,630 US20090239951A1 (en) | 2006-03-28 | 2007-03-27 | Crystalline Material |
BRPI0710120-1A BRPI0710120A2 (en) | 2006-03-28 | 2007-03-27 | improved crystalline material |
NZ570684A NZ570684A (en) | 2006-03-28 | 2007-03-27 | Improved crystalline material |
EP07723633A EP2004593B1 (en) | 2006-03-28 | 2007-03-27 | Improved crystalline material |
AT07723633T ATE550314T1 (en) | 2006-03-28 | 2007-03-27 | IMPROVED CRYSTALLINE MATERIAL |
CA002642872A CA2642872A1 (en) | 2006-03-28 | 2007-03-27 | Improved crystalline material |
JP2009501928A JP2009531358A (en) | 2006-03-28 | 2007-03-27 | Improved crystalline material |
MX2008012393A MX2008012393A (en) | 2006-03-28 | 2007-03-27 | Improved crystalline material. |
NO20083588A NO20083588L (en) | 2006-03-28 | 2008-08-19 | Improved crystalline material |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0606201.2A GB0606201D0 (en) | 2006-03-28 | 2006-03-28 | Improved crytalline material |
GB0606201.2 | 2006-03-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007110225A1 true WO2007110225A1 (en) | 2007-10-04 |
Family
ID=36424732
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2007/002687 WO2007110225A1 (en) | 2006-03-28 | 2007-03-27 | Improved crystalline material |
Country Status (16)
Country | Link |
---|---|
US (1) | US20090239951A1 (en) |
EP (2) | EP2004593B1 (en) |
JP (1) | JP2009531358A (en) |
KR (1) | KR20090014342A (en) |
CN (1) | CN101421229A (en) |
AT (1) | ATE550314T1 (en) |
AU (1) | AU2007229718A1 (en) |
BR (1) | BRPI0710120A2 (en) |
CA (1) | CA2642872A1 (en) |
GB (1) | GB0606201D0 (en) |
MX (1) | MX2008012393A (en) |
NO (1) | NO20083588L (en) |
NZ (1) | NZ570684A (en) |
RU (1) | RU2444513C2 (en) |
WO (1) | WO2007110225A1 (en) |
ZA (1) | ZA200807596B (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012120054A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
WO2012120052A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
WO2012120055A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
WO2012120053A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
WO2012120056A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
EP2695611A1 (en) | 2012-08-06 | 2014-02-12 | Dr. August Wolff GmbH & Co. KG Arzneimittel | Eprotirome for use in the prevention and/or treatment of hair disorders and compositions thereof |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001060784A1 (en) | 2000-02-17 | 2001-08-23 | Bristol-Myers Squibb Co. | Aniline-derived ligands for the thyroid receptor |
WO2001072692A1 (en) * | 2000-03-31 | 2001-10-04 | Pfizer Products Inc. | Malonamic acids and derivatives thereof as thyroid receptor ligands |
WO2001085670A1 (en) * | 2000-05-12 | 2001-11-15 | Kissei Pharmaceutical Co., Ltd. | Malonanilic acid derivatives, medicinal compositions containing the same and use thereof |
WO2002094319A1 (en) * | 2001-05-18 | 2002-11-28 | Kissei Pharmaceutical Co., Ltd. | Preventive or recurrence-suppressive agents for liver cancer |
US20030057671A1 (en) | 2001-04-12 | 2003-03-27 | Axel Schaedler | Four wheel steering system |
US20030157671A1 (en) | 2001-11-02 | 2003-08-21 | Ramakrishnan Chidambaram | Process for the preparation of aniline-derived thyroid receptor ligands |
WO2004067482A2 (en) * | 2003-01-24 | 2004-08-12 | Bristol-Myers Squibb Company | Substituted anilide ligands for the thyroid receptor |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3450751A (en) * | 1963-06-15 | 1969-06-17 | Noguchi Inst The | Continuous optical resolution of racemic glutamic acid or its salts |
GB9220137D0 (en) * | 1992-09-23 | 1992-11-04 | Pfizer Ltd | Therapeutic agents |
-
2006
- 2006-03-28 GB GBGB0606201.2A patent/GB0606201D0/en not_active Ceased
-
2007
- 2007-03-27 AU AU2007229718A patent/AU2007229718A1/en not_active Abandoned
- 2007-03-27 AT AT07723633T patent/ATE550314T1/en active
- 2007-03-27 CA CA002642872A patent/CA2642872A1/en not_active Abandoned
- 2007-03-27 EP EP07723633A patent/EP2004593B1/en not_active Not-in-force
- 2007-03-27 WO PCT/EP2007/002687 patent/WO2007110225A1/en active Application Filing
- 2007-03-27 EP EP11171176A patent/EP2368873A1/en not_active Withdrawn
- 2007-03-27 JP JP2009501928A patent/JP2009531358A/en active Pending
- 2007-03-27 BR BRPI0710120-1A patent/BRPI0710120A2/en not_active IP Right Cessation
- 2007-03-27 MX MX2008012393A patent/MX2008012393A/en not_active Application Discontinuation
- 2007-03-27 KR KR1020087025952A patent/KR20090014342A/en not_active Application Discontinuation
- 2007-03-27 US US12/225,630 patent/US20090239951A1/en not_active Abandoned
- 2007-03-27 RU RU2008142528/04A patent/RU2444513C2/en not_active IP Right Cessation
- 2007-03-27 NZ NZ570684A patent/NZ570684A/en not_active IP Right Cessation
- 2007-03-27 CN CNA2007800108211A patent/CN101421229A/en active Pending
-
2008
- 2008-08-19 NO NO20083588A patent/NO20083588L/en not_active Application Discontinuation
- 2008-09-03 ZA ZA200807596A patent/ZA200807596B/en unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001060784A1 (en) | 2000-02-17 | 2001-08-23 | Bristol-Myers Squibb Co. | Aniline-derived ligands for the thyroid receptor |
WO2001072692A1 (en) * | 2000-03-31 | 2001-10-04 | Pfizer Products Inc. | Malonamic acids and derivatives thereof as thyroid receptor ligands |
WO2001085670A1 (en) * | 2000-05-12 | 2001-11-15 | Kissei Pharmaceutical Co., Ltd. | Malonanilic acid derivatives, medicinal compositions containing the same and use thereof |
US20030057671A1 (en) | 2001-04-12 | 2003-03-27 | Axel Schaedler | Four wheel steering system |
WO2002094319A1 (en) * | 2001-05-18 | 2002-11-28 | Kissei Pharmaceutical Co., Ltd. | Preventive or recurrence-suppressive agents for liver cancer |
US20030157671A1 (en) | 2001-11-02 | 2003-08-21 | Ramakrishnan Chidambaram | Process for the preparation of aniline-derived thyroid receptor ligands |
WO2004067482A2 (en) * | 2003-01-24 | 2004-08-12 | Bristol-Myers Squibb Company | Substituted anilide ligands for the thyroid receptor |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012120054A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
WO2012120052A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
WO2012120055A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
WO2012120053A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
WO2012120056A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
EP2695611A1 (en) | 2012-08-06 | 2014-02-12 | Dr. August Wolff GmbH & Co. KG Arzneimittel | Eprotirome for use in the prevention and/or treatment of hair disorders and compositions thereof |
WO2014023698A1 (en) | 2012-08-06 | 2014-02-13 | Dr. August Wolff Gmbh & Co. Kg Arzneimitttel | Eprotirome for use in the prevention and/or treatment of hair disorders and compositions thereof |
Also Published As
Publication number | Publication date |
---|---|
CN101421229A (en) | 2009-04-29 |
ZA200807596B (en) | 2009-11-25 |
EP2004593B1 (en) | 2012-03-21 |
AU2007229718A1 (en) | 2007-10-04 |
NZ570684A (en) | 2011-07-29 |
RU2444513C2 (en) | 2012-03-10 |
MX2008012393A (en) | 2009-03-02 |
RU2008142528A (en) | 2010-05-10 |
ATE550314T1 (en) | 2012-04-15 |
KR20090014342A (en) | 2009-02-10 |
GB0606201D0 (en) | 2006-05-10 |
BRPI0710120A2 (en) | 2011-08-02 |
CA2642872A1 (en) | 2007-10-04 |
EP2004593A1 (en) | 2008-12-24 |
NO20083588L (en) | 2008-11-12 |
EP2368873A1 (en) | 2011-09-28 |
US20090239951A1 (en) | 2009-09-24 |
JP2009531358A (en) | 2009-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2004593B1 (en) | Improved crystalline material | |
HRP20161672T1 (en) | New crystalline form vi of agomelatine, method of preparation and pharmaceutical compositions thereof | |
CA2336853C (en) | Phenoxyacetic acid derivatives and medicinal compositions containing the same | |
EA008473B1 (en) | New process for the synthesis and new crystalline form of agomelatine and pharmaceutical compositions containing it | |
EA015545B1 (en) | New method for synthesis agomelatine | |
WO2007062190A2 (en) | Chemical compounds | |
ZA200600819B (en) | Cycloalkylidene compounds as modulators of estrogen receptor | |
JP2012519715A (en) | Novel crystalline form VI of Agomelatine, production method and application thereof | |
HRP20040250A2 (en) | Crystals of hydroxynorephedrine derivative | |
CA2674764C (en) | New process for synthesizing agomelatine | |
WO2000043016A1 (en) | DICARBA-closo-DODECABORANE DERIVATIVES | |
CA2298493C (en) | Aminoethylphenoxyacetic acid derivatives and drugs for pain remission and calculi removal promotion in urinary lithiasis | |
JPH08291106A (en) | Production of optically active 2-propyloctanoic acid | |
JP2015521179A (en) | Agomelatine acid group composite and its production method and use | |
JP7426832B2 (en) | Iguratimod with a novel crystal structure and its production method | |
JP6595990B2 (en) | NOVEL COMPLEX OF AGOMELATIN AND SULFONIC ACID, METHOD FOR PRODUCING THEM, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | |
AU2014298230C1 (en) | Novel forms of co-crystals of agomelatine and p-toluenesulphonic acid, method for preparing same and the pharmaceutical compositions containing same | |
CA1097682A (en) | Process for the production of phenylacetic acid derivatives | |
JP4014138B2 (en) | Production intermediate | |
EP1745016A1 (en) | Process for the preparation of substituted tetralin and substituted indane derivatives | |
CZ302572B6 (en) | Crystalline polymorphous form of aminoethylphenoxyacetic acid derivative | |
KR20160035598A (en) | Novel forms of co-crystals of agomelatine and p-toluenesulphonic acid, method for preparing same and the pharmaceutical compositions containing same | |
FR2656607A1 (en) | Phenylethanolaminomethyltetralins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07723633 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2642872 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 570684 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007229718 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 7715/DELNP/2008 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2007229718 Country of ref document: AU Date of ref document: 20070327 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 194316 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200780010821.1 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009501928 Country of ref document: JP Ref document number: MX/A/2008/012393 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020087025952 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007723633 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2008142528 Country of ref document: RU Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12225630 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0710120 Country of ref document: BR Kind code of ref document: A2 Effective date: 20080929 |